Share 'Continued Access to Drisapersen for Patients Completing the US Ph IIb 48-week study'
Below is the latest update PPMD has received from Dr. Rohit Batta, Global Medical Affairs and Patient Relations Leader in GSK's Rare Disease Unit :
The purpose of this communication is provide an update to you, as you have requested, on GSK’s plans for providing the option of continued access to drisapersen for boys completing the US Ph IIb 48 week study (DMD114876) - clinicaltrials.gov.
GSK is c…
You can share this blog post in two ways…
Share this link:
Send it with your computer's email program: Email this